Midas Minerals and Kuda Gold recorded the best lithium exploration results this morning
There were a flurry of lithium exploration results this morning, but Midas Minerals (ASX:MM1) and Kuda Gold (ASX:KGD) stood out. The former of these lithium stocks recorded amongst the highest-grade results recorded in several weeks.
Midas Minerals records up to 7.25% lithium
Midas has a project in Canada’s Northwest Territories. Although it is at early stage exploration – at the sampling stage rather than drilling – it now has 30 samples and the results are not to be snuffed at. The best result was 7.25% lithium, with others including 5.55%, 5.12% and 3.97%.
The company claims that it has covered less than 1% of the project area, so there is scope for further discoveries. Nonetheless, it as immediately applied for a drilling permit in those areas.
Kuda Gold is prospecting for lithium
Notwithstanding this company’s name, one of is projects is the Kirup lithium project that lies just 20km from the Greenbushes lithium mine in WA. Unlike Midas, Kuda is at the drilling stage, although it has not reported formal grades. Rather, it reported visual pegmatites in multiple intervals varying from 3m to interpreted 55m thick.
Pegmatite is an igneous rock that is created underground when interlocking crystals. Even though mere pegmatites do not imply the presence of lithium, as the company stressed, pegmatites can be a common source for lithium. And this is why share in this company rose this morning.
What are the Best ASX Stocks to invest in right now?
Check our ASX buy/sell tips
Blog Categories
Get the Latest Insider Trades on ASX!
Recent Posts
Nvidia Says US$1T by 2027, Here’s the Hardware Shift It’s Banking On
Nvidia’s US$1T Goal Just Raised the Stakes for Inference Nvidia CEO Jensen Huang has just held the company’s biggest annual…
AML3D (ASX:AL3) Record A$9.9m US Navy Shipbuilder Order Sparks a Rerate
Newport News Doubles Down, Four Arcemy X Systems Ordered AML3D surged today after announcing a A$9.9M contract with the US’s…
T-Cell Lymphoma is a very deadly cancer, but this ASX stock has a treatment in a Phase 2 trial!
Prescient Therapeutics‘ (ASX:PTX) trial of PTX-100 against T-Cell Lymphoma is well and truly underway now with 8 out of…